Literature DB >> 61283

Equine infectious anemia virus: evidence favoring classification as a retravirus.

H P Charman, S Bladen, R V Gilden, L Coggins.   

Abstract

Equine infectious anemia virus (EIAV) has a density of 1.154 g/cm3 in sucrose a high-molecular-weight RNA similar in size to Rauscher murine leukemia virus, and an internal virion reverse transcriptase that utilizes the synthetic RNA template poly(rA) but not the synthetic DNA template poly(dA), both with (dT)12 as primer. Although capable of utilizing manganese at low concentrations (approximately 0.1 mM), EIAV reverse transcriptase showed highest activity in the presence of 9 mM magnesium. The major protein of EIAV has a slightly lower molecular weight than the comparable protein of type C viruses and co-electrophoresed with 125I-labeled p25 of Mason-Pfizer monkey virus. A reference horse serum with antibodies to the major EIAV protein reacted only with EIAV and not with other type C or non-type C retraviruses. Reciprocally, a broadly reactive serum to type C virus p30s and specific sera to a variety of non-type C retraviruses did not react with EIAV. We recommend the inclusion of EIAV in the family Retraviridae.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 61283      PMCID: PMC354947     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Immunization with a lipid-conjugated membrane antigen to suppress growth of a fibrosarcoma induced by simian virus 40.

Authors:  R L Hunter; F Strickland
Journal:  J Natl Cancer Inst       Date:  1975-05       Impact factor: 13.506

3.  Symposium: characterization of oncornaviruses and related viruses--a report.

Authors:  A J Dalton; U I Heine; J L Melnick
Journal:  J Natl Cancer Inst       Date:  1975-10       Impact factor: 13.506

4.  The structural polypeptides of RNA slow viruses.

Authors:  A T Haase; J R Baringer
Journal:  Virology       Date:  1974-01       Impact factor: 3.616

5.  Humoral immune responses of cats to mammalian type-C virus p30s.

Authors:  H P Charman; M B Gardner; R M McAllister; N Kim; R V Gilden
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

6.  Biology of feline leukemia virus in the natural environment.

Authors:  W D Hardy; P W Hess; E G MacEwen; A J McClelland; E E Zuckerman; M Essex; S M Cotter; O Jarrett
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

7.  Natural and experimentally induced antibodies to defined mammalian type-C virus proteins in primates.

Authors:  H P Charman; N Kim; M White; H Marquardt; R V Gilden; T Kawakami
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

8.  Induction of syncytia by the bovine C-type leukemia virus.

Authors:  C A Diglio; J F Ferrer
Journal:  Cancer Res       Date:  1976-03       Impact factor: 12.701

9.  Humoral immune responses of cats to feline leukemia virus: comparison of responses to the major structural protein p30 and to a virus-specific cell membrane antigen (FOCMA).

Authors:  H P Charman; N Kim; R V Gilden; W D Hardy; M Essex
Journal:  J Natl Cancer Inst       Date:  1976-04       Impact factor: 13.506

10.  Characterization and separation of viral DNA polymerase in mouse milk.

Authors:  R S Howk; L A Rye; L A Killeen; E M Scolnick; W P Parks
Journal:  Proc Natl Acad Sci U S A       Date:  1973-07       Impact factor: 11.205

View more
  29 in total

1.  The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro.

Authors:  S T Perry; M T Flaherty; M J Kelley; D L Clabough; S R Tronick; L Coggins; L Whetter; C R Lengel; F Fuller
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Antigenic variation of equine infectious anemia virus as detected by virus neutralization. Brief report.

Authors:  Y Kono
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

3.  The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells.

Authors:  E Priel; S D Showalter; M Roberts; S Oroszlan; D G Blair
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Biological characterization of avian osteopetrosis.

Authors:  A J Banes; R E Smith
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

Review 5.  Lentiviruses are etiological agents of chronic diseases in animals and acquired immunodeficiency syndrome in humans.

Authors:  O Narayan
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

6.  Electron microscopic studies on equine infectious anemia virus (EIAV). Brief report.

Authors:  F Weiland; H D Matheka; L Coggins; D Hatner
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

Review 7.  Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus-1 gp41 and equine infectious anemia virus gp45.

Authors:  Liangwei Duan; Jiansen Du; Xinqi Liu
Journal:  Protein Sci       Date:  2015-09-21       Impact factor: 6.725

8.  Structural proteins of equine infectious anemia virus.

Authors:  W P Cheevers; C M Ackley; T B Crawford
Journal:  J Virol       Date:  1978-12       Impact factor: 5.103

9.  Specificity of response to viral proteins in horses infected with equine infectious anemia virus.

Authors:  H Charman; C Long; L Coggins
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

10.  Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop.

Authors:  Z Chen; P Telfier; A Gettie; P Reed; L Zhang; D D Ho; P A Marx
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.